mesothelin UCAR-T

Mesothelin UCAR-T is an allogeneic (universal) chimeric antigen receptor T-cell (CAR-T) therapy developed by Zhongshan People's Hospital for the treatment of mesothelin-positive advanced gynecological tumors. The therapy utilizes T-cells from healthy donors that are engineered to express a chimeric antigen receptor (CAR) targeting mesothelin (MSLN), a cell surface glycoprotein frequently overexpressed in cancers such as ovarian, endometrial, and cervical cancer. To enable "off-the-shelf" use and prevent graft-versus-host disease (GVHD), these universal CAR-T cells typically undergo gene editing to disrupt the T-cell receptor (TCR) and/or major histocompatibility complex (MHC) genes. This approach aims to provide a more accessible and standardized treatment option compared to patient-specific autologous CAR-T therapies.

Other names

Mesothelin-targeted Universal CAR-T Cells